A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Status:
Completed
Trial end date:
2020-08-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a
targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine
and cisplatin alone in participants with stomach cancer.